Janux Therapeutics (NASDAQ:JANX) Sees Unusually-High Trading Volume – Here’s Why

Janux Therapeutics, Inc. (NASDAQ:JANX) shares saw an uptick in trading volume on Thursday . 3,145,843 shares traded hands during mid-day trading, an increase of 94% from the previous session’s volume of 1,622,445 shares.The stock last traded at $14.32 and had previously closed at $13.27.

Trending Headlines about Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

• Positive Sentiment: Janux and Bristol Myers Squibb announced a global collaboration and exclusive worldwide license to develop a tumor?activated therapeutic for solid tumors — strategic validation from a large pharma partner that should de?risk Janux’s platform and build long?term value. Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug (Reuters)
• Positive Sentiment: Reports value the transaction at roughly $800M–$850M in potential payments (upfront, milestones, royalties) — a material financing and validation event that investors typically view favorably for biotech partners. Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million (Benzinga)
• Positive Sentiment: Coverage emphasizes that the deal licenses Janux’s tumor?activated platforms, potentially accelerating development in solid tumors and extending Janux’s reach beyond its internal resources. JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
• Neutral Sentiment: Widespread media and aggregator coverage (pre?market and post?announcement) amplified the story and short?term volatility; several outlets simply repeated the press release without new details. Janux Therapeutics stock soars after Bristol Myers Squibb collaboration (Investing)
• Neutral Sentiment: Company press release provided the formal terms and R&D focus; media republished the release across outlets (Yahoo/MSN summaries). These confirm the headline but add little incremental financial detail. Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb (Yahoo)
• Negative Sentiment: Clear Street cut JANX to a “Hold” shortly after the announcement, a downgrade that can pressure the stock if other brokers follow or if investors interpret the move as signaling limited near?term upside. Janux Therapeutics (NASDAQ:JANX) Cut to “Hold” at Clear Str (American Banking News)
• Negative Sentiment: After the initial gap higher, JANX has retreated — likely a mix of profit?taking and the downgrade; technicals show the stock below its 50? and 200?day moving averages, which may cap near?term rallies absent further catalysts. (Background market data summarized from public trading statistics.)

Analyst Upgrades and Downgrades

A number of research firms have commented on JANX. Piper Sandler reduced their target price on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a report on Friday, January 16th. UBS Group reaffirmed a “buy” rating and set a $57.00 price objective on shares of Janux Therapeutics in a research note on Tuesday, December 2nd. Wolfe Research initiated coverage on Janux Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Janux Therapeutics in a report on Thursday. Finally, Clear Str lowered Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $60.08.

Janux Therapeutics Stock Performance

The firm has a market cap of $890.82 million, a P/E ratio of -8.82 and a beta of 2.88. The firm has a fifty day moving average of $18.26 and a 200-day moving average of $22.75.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. Equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In related news, CEO David Alan Campbell sold 8,072 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $110,828.56. Following the completion of the sale, the chief executive officer directly owned 284,982 shares in the company, valued at approximately $3,912,802.86. The trade was a 2.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Andrew Hollman Meyer sold 16,665 shares of Janux Therapeutics stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $30.06, for a total value of $500,949.90. Following the completion of the transaction, the insider owned 82,139 shares in the company, valued at $2,469,098.34. The trade was a 16.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 42,364 shares of company stock valued at $972,185 in the last ninety days. Company insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

Hedge funds have recently made changes to their positions in the business. Orbimed Advisors LLC grew its holdings in shares of Janux Therapeutics by 45.9% during the third quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company’s stock worth $43,163,000 after purchasing an additional 555,800 shares during the last quarter. Readystate Asset Management LP raised its stake in Janux Therapeutics by 38.0% during the 3rd quarter. Readystate Asset Management LP now owns 960,379 shares of the company’s stock worth $23,472,000 after buying an additional 264,423 shares during the period. Vanguard Group Inc. increased its stake in Janux Therapeutics by 10.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,417,104 shares of the company’s stock worth $59,074,000 after purchasing an additional 227,676 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Janux Therapeutics by 42.5% in the third quarter. Wellington Management Group LLP now owns 701,604 shares of the company’s stock valued at $17,147,000 after purchasing an additional 209,243 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its position in Janux Therapeutics by 64.2% during the 3rd quarter. Alyeska Investment Group L.P. now owns 424,845 shares of the company’s stock worth $10,383,000 after acquiring an additional 166,167 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.